News - Cardio-vascular


Current filters:


Popular Filters

501 to 525 of 526 results

Disappointing FDA briefing papers on Bayer/J&J’s Xarelto


US Food and Drug Administration staffers posted a negative picture for German drug major Bayer (BAY:…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

AstraZeneca’s Crestor fails to show significant improvement over Lipitor


There was a big disappointment for Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Friday, when it…


Pfizer in generic Lipitor deals with Sanofi and Dr Reddy’s


Global drugs behemoth Pfizer (NYSE: PFE) has reached agreement with French drug major Sanofi (Euronext:…

atorvastatinCardio-vascularDr Reddy's LaboratoriesGenericsLegalLicensingLipitorPfizerSanofiZentiva

RUBY-1 trial shows Astellas’ blood thinner darexaban increases bleeding


A Phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban, under development…

Astellas PharmaCardio-vasculardarexabanPharmaceuticalResearch

Bristol-Myers and Pfizer’s Eliquis first oral anticoagulant to significantly reduce all-cause death


In much anticipated research news, US drug majors Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE:…

apixabanBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalResearch

AstraZeneca’s Brilinta shows mortality benefit over gold-standard Plavix


There was good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday, when the firm revealed…


AstraZeneca blood thinner Brilinta now available in USA


Anglo-Swedish pharmaceutical major AstraZeneca (LSE: AZN) said yesterday that Brilinta (ticagrelor) tablets,…

AstraZenecaBrilintaCardio-vascularMarkets & MarketingNorth AmericaPharmaceutical

Spotlight on Roche dalcetrapib data to be presented at ESC


An abstract summarizing partial results from the Phase II dal-PLAQUE trial with Swiss drug major Roche’s…


Not faster, but longer - new drug omecamtiv mecarbil changes beat in treating heart failure


A new drug which offers a radically different approach to treating certain types of heart failure has…

AmgenCardio-vascularCytokineticsomecamtiv mecarbilPharmaceuticalResearch

Gentium withdraws US NDA for defibrotide


Italian drug developer Gentium SpA (Nasdaq: GENT) saw its shares price plunge 29% to $6.22 on the Nasdaq…

Cardio-vasculardefibrotideGentiumNorth AmericaPharmaceuticalRegulationSigma Tau

NEJM report confirms Xarelto as safe and effective as warfarin, says Bayer


Data newly-published in the New England Journal of Medicine (NEJM) demonstrate that German drug major…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

No proof fibrate drugs reduce heart risk in diabetes patients on statins


Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of…


Tentative OK from US FDA for Watson's rosuvastatin zinc tablets


US drugmaker Watson Pharmaceuticals (NYSE: WPI) says that its subsidiary, Watson Laboratories, has received…

AstraZenecaCardio-vascularCrestorGenericsNorth AmericaRegulationrosuvastatinWatson Pharmaceuticals

EU approves Boehringer’s Pradaxa for stroke prevention in atrial fibrillation


There was good news for independent German drug major Boehringer Ingelheim yesterday, when the company…

BayerBoehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulationXarelto

Daiichi Sankyo and Ranbaxy expand business in Mexico with launch of olmesartan


Japanese drug major Daiichi Sankyo (TYO: 4568) and its 64% owned Indian affiliate Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoGenericsMarkets & MarketingolmesartanRanbaxy LaboratoriesSouth America

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in…

Ariad PharmaceuticalsAstraZenecaAxanumCardio-vascularEuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

Hypercholesterolemia therapeutics market forecast to show moderate growth


The value of the global hypercholesterolemia therapeutics - cholesterol lowerers - market was put at…

Cardio-vascularMarkets & MarketingPharmaceuticalResearch

UK’s NICE backs use of TMC’s Angiox for STEMI patients undergoing primary PCI


Following a previous positive draft guidance, the UK drugs watch dog the National Institute for Health…

AngioxCardio-vascularEuropePharmaceuticalPricingRegulationThe Medicines Company

Merck & Co gets North American and Mexican rights to vernakalant iv from Astellas


US drug giant Merck & Co (NYSE: MRK) has entered into an agreement with Japan’s Astellas Pharma…

Astellas PharmaCardio-vascularCardiome PharmaLicensingMerck & CoNorth AmericaPharmaceuticalvernakalant

US FDA now joins in probe of Sanofi’s Multaq safety


The US Food and Drug Administration says it is reviewing data from a clinical trial that was evaluating…

Cardio-vascularMultaqNorth AmericaPharmaceuticalRegulationSanofi

Merck & Co sets up China marketing JV with Simcere


US pharma giant Merck & Co (NYSE: MRK) has signed a framework agreement with leading Chinese drugmaker…

Asia-PacificCardio-vascularDiabetesGenericsMarkets & MarketingMerck & CoPharmaceuticalSimcere Pharmaceutical

US FDA at last approves AstraZeneca blood-thinning drug Brilinta


There was much awaited good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) last night, when…

AstraZenecaBrilintaCardio-vascularNorth AmericaPharmaceuticalRegulation

Daiichi Sankyo debuts Lixiana in Japan for VTE prevention after orthopedic surgery


Building on its cardiovascular portfolio, Japanese drug major Daiichi Sankyo (TYO: 4568) has launched…

Asia-PacificCardio-vascularEisaiLixianaMarkets & MarketingPharmaceutical

501 to 525 of 526 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top